Patient Preferences

Credible patient preference information to support optimal product development and value communication

Services & Products

  • Publications

    Publication

    Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States. Value Health. 2017 Jan;20(1):132-140. doi: 10.1016/j.jval.2016.08.724. Epub 2016 Oct 5. ABSTRACT

    Publication

    Multiple Criteria Decision Analysis for Health Care Decision Making-Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016 Mar;19(2):125-37. doi: 10.1016/j.jval.2015.12.016. Epub 2016 Mar 7. ABSTRACT

    Publication

    Evaluating Preferences for Profiles of GLP-1 Receptor Agonists among Injection-Naive Type 2 Diabetes Patients in the UK. Patient Prefer Adherence. 2015 Nov 9; 9:1611-1622. ABSTRACT
    See More
  • Webinars

    Webinar

    Quantitative Benefit-Risk Assessment in Drug Development

    Presenters: Tommi Tervonen, PhD, Research Scientist, Outcomes Research, Evidera; Kevin Marsh, PhD, Senior Research Scientist and Executive Director, OR, Evidera

    Additional Info
    Contact us for slides

    Webinar

    Incorporating Patient Preferences into Product Development and Value Communication

    Presenters: Kevin Marsh, PhD, Executive Director, Senior Research Scientist, Modeling & Simulation, Evidera; John F. P. Bridges, PhD, Associate Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health

    FIRST OF 3-PART SERIES ON PATIENT PREFERENCE

    Additional Info
    Contact us for slides

    Webinar

    Which Method to Use for Capturing Patient Preferences in Benefit-Risk Assessment

    Presenters: Heather Gelhorn, PhD, Senior Research Scientist, Outcomes Research, Evidera; Katharine Gries, PharmD, PhD, formerly with Evidera; Tommi Tervonen, PhD, Senior Research Associate, Modeling & Simulation, Evidera

    SECOND OF 3-PART SERIES ON PATIENT PREFERENCE

    Additional Info
    Contact us for slides
  • White Papers

    Whitepaper

    Incorporating Patient Preferences into Product Development and Value Communication: Why, When and How?

    Authors: Kevin Marsh, PhD, Evidera

    Year: 2016

    View
    See More
  • Presentations

    Session Speaker

    Incorporating Patient Preferences in Drug Development and Approval

    DIA 2017:

    Chicago, IL, USA
    18-Jun-2017

    Authors/Presenters: Marsh K

    Year: 2017

    Symposium

    Who To Ask and How? Preference-Based Methods for Benefit-Risk Assessment

    32nd ICPE:

    Dublin, Ireland
    25-Aug-2016

    Authors/Presenters: Marsh K, Hillege HL, Ataher Q, Tervonen T

    Year: 2016

    Workshop

    W19: Patient-Centered Benefit-Risk Analysis: Regulatory Developments and Prospects

    ISPOR 21st Annual International Meeting – 2016:

    Washington, DC, USA
    21-May-2016

    Authors/Presenters: Luce B, Ho M, Gerson J, Eggers S

    Year: 2016

    See More
  • Fact Sheets

    Fact Sheet

    Using Patient Preferences to Support Product Development and Value Communication
    Download

Most people would recognize that patient preferences have an important role to play in healthcare decision making, although it is only recently that decision makers have shown interest in quantitative methods for eliciting patient preferences. For example:

  • The U.S. Food and Drug Administration (FDA) recently made its first regulatory approval based on preference data, and may encourage manufacturers to include patient preference data in submissions under some circumstances
  • The European Medicines Agency (EMA) is assessing the feasibility and usefulness of methods for eliciting individual patient preferences
  • In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) has recommended patient preferences are used to inform economic evaluation

Powerful data with a range of applications

Data on patients’ trade-offs can be used to generate decision relevant information, including: the minimum acceptable benefit to offset treatment risks; the maximum acceptable risk that would be justified by treatment benefits; overall benefit-risk profile; willingness to pay; and the probability that a patient selects or adheres to a particular treatment.

This patient preference information is used to help with:

  • Product development,  informing treatment features and target population
  • Trial design, including endpoint election and sample size calculations
  • Regulatory submissions,  demonstrating overall benefit-risk profile
  • Payer and clinician value communication

How can we help you?

With one of the largest in-house teams, and a unique combination of experience in both preference elicitation and decision analysis, Evidera has the expertise to ensure you generate preference information that meets the needs of decision makers, including:

Offerings

Preference Elicitation

Expertise in a diversity of preference elicitation methods, in particular discrete choice experiments and swing weighting.

Patient Recruitment

Expertise in recruiting patients through panels, advocacy groups, and sites.

Multi-criteria decision analysis

Methods to combine preference data with performance data to inform decisions. Click here to learn more.

Uncertainty analysis

Methods to assess the impact of uncertainty on analysis outputs, including Stochastic Multi-criteria Acceptability Analysis.

Experience interacting with regulators

Experience interacting with regulators, including all FDA divisions.

Patient Preferences Experts

Services & Products

  • Publications

    Publication

    Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States. Value Health. 2017 Jan;20(1):132-140. doi: 10.1016/j.jval.2016.08.724. Epub 2016 Oct 5. ABSTRACT

    Publication

    Multiple Criteria Decision Analysis for Health Care Decision Making-Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016 Mar;19(2):125-37. doi: 10.1016/j.jval.2015.12.016. Epub 2016 Mar 7. ABSTRACT

    Publication

    Evaluating Preferences for Profiles of GLP-1 Receptor Agonists among Injection-Naive Type 2 Diabetes Patients in the UK. Patient Prefer Adherence. 2015 Nov 9; 9:1611-1622. ABSTRACT
    See More
  • Webinars

    Webinar

    Quantitative Benefit-Risk Assessment in Drug Development

    Presenters: Tommi Tervonen, PhD, Research Scientist, Outcomes Research, Evidera; Kevin Marsh, PhD, Senior Research Scientist and Executive Director, OR, Evidera

    Additional Info
    Contact us for slides

    Webinar

    Incorporating Patient Preferences into Product Development and Value Communication

    Presenters: Kevin Marsh, PhD, Executive Director, Senior Research Scientist, Modeling & Simulation, Evidera; John F. P. Bridges, PhD, Associate Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health

    FIRST OF 3-PART SERIES ON PATIENT PREFERENCE

    Additional Info
    Contact us for slides

    Webinar

    Which Method to Use for Capturing Patient Preferences in Benefit-Risk Assessment

    Presenters: Heather Gelhorn, PhD, Senior Research Scientist, Outcomes Research, Evidera; Katharine Gries, PharmD, PhD, formerly with Evidera; Tommi Tervonen, PhD, Senior Research Associate, Modeling & Simulation, Evidera

    SECOND OF 3-PART SERIES ON PATIENT PREFERENCE

    Additional Info
    Contact us for slides
  • White Papers

    Whitepaper

    Incorporating Patient Preferences into Product Development and Value Communication: Why, When and How?

    Authors: Kevin Marsh, PhD, Evidera

    Year: 2016

    View
    See More
  • Presentations

    Session Speaker

    Incorporating Patient Preferences in Drug Development and Approval

    DIA 2017:

    Chicago, IL, USA
    18-Jun-2017

    Authors/Presenters: Marsh K

    Year: 2017

    Symposium

    Who To Ask and How? Preference-Based Methods for Benefit-Risk Assessment

    32nd ICPE:

    Dublin, Ireland
    25-Aug-2016

    Authors/Presenters: Marsh K, Hillege HL, Ataher Q, Tervonen T

    Year: 2016

    Workshop

    W19: Patient-Centered Benefit-Risk Analysis: Regulatory Developments and Prospects

    ISPOR 21st Annual International Meeting – 2016:

    Washington, DC, USA
    21-May-2016

    Authors/Presenters: Luce B, Ho M, Gerson J, Eggers S

    Year: 2016

    See More
  • Fact Sheets

    Fact Sheet

    Using Patient Preferences to Support Product Development and Value Communication
    Download
Back to Top